DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Defense Health Agency Contracting Activity - DHACAAmount not specifiedDue Sep 30, 2026

Researchers Schools & universities Broad eligibility

Deadline: Sep 30, 2026
Posted: May 4, 2026
Award amount: Amount not specified
Focus areas: Science and Technology and other Research and Development

Don’t miss this deadline

We’ll email you before Sep 30, 2026 so you have time to apply.

In plain English

This Department of War (Defense Health Agency) ALS Research Program Therapeutic Development Award supports research from preclinical validation of therapeutic leads through FDA IND-enabling studies, with product-driven, empirical projects. Eligibility is described as unrestricted (open to any entity type), subject to clarifications. Applicants must begin with lead compounds in hand and already-demonstrated proof-of-concept efficacy in a preclinical ALS model; candidates already granted an IND are not appropriate. No specific award amount is stated.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

About this grant

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology. Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems. Distinctive Features: Mechanism-specific , predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award . If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported. Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Science and Technology and other Research and Development — soonest deadline first.

Also listed under Defense Health Agency Contracting Activity - DHACA and Science & Research Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.